Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Accumulated Expenses (2016 - 2025)

Regen BioPharma (RGBPP) has disclosed Accumulated Expenses for 12 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 8.46% to $1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.9 million, a 8.46% increase, with the full-year FY2025 number at $1.8 million, up 10.42% from a year prior.
  • Accumulated Expenses was $1.9 million for Q4 2025 at Regen BioPharma, up from $1.8 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $1.9 million in Q4 2025 to a low of $4241.0 in Q1 2021.
  • A 5-year average of $762669.4 and a median of $503601.5 in 2022 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: crashed 99.56% in 2022, then skyrocketed 41733.48% in 2025.
  • Regen BioPharma's Accumulated Expenses stood at $4241.0 in 2021, then changed by 0.0% to $4241.0 in 2022, then changed by 0.0% to $4241.0 in 2023, then surged by 40165.98% to $1.7 million in 2024, then grew by 8.46% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for RGBPP's Accumulated Expenses are $1.9 million (Q4 2025), $1.8 million (Q3 2025), and $1.8 million (Q2 2025).